Perminder Bhatia, MD
Neurology · Fresno, CANPI 1013002328
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $191,873 of the $279,220 with a category attached, or 68.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.7%. 2025 is the largest year on record at $82,629, 4.7 times the $17,503 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,933 payments — averaging $144.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$49K
- Lilly USA, LLC$34K
- Eisai Inc.$32K
- Teva Pharmaceuticals USA, Inc.$30K
- Otsuka America Pharmaceutical, Inc.$29K
- SK Life Science, Inc.$28K
- plus $75K from 54 others
Across 777 payments — averaging $10,275 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.8M
- Biogen$1.1M
- AbbVie$720K
- UCB SA$697K
- Novartis$343K
- Vertex$182K
- plus $1.1M from 20 others
What the payments were for
- Consulting fees$23,2388%
- Speaking & faculty fees$191,87369%
- Travel & lodging$24,7659%
- Food & beverage$38,72214%
- Education$6230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$35,656
- KISUNLA$32,979
- Leqembi$30,686
- Austedo XR$28,637
- REXULTI$28,527
- QULIPTA$22,925
- XCOPRI$20,698
- Symbravo$13,838
- INBRIJA$12,017
- Cenobamate$5,503
- NURTEC ODT$5,375
- GENERAL DBS$2,228
- Bafiertam$1,700
- VNS Therapy$1,500
- MYOBLOC$1,061
- VERCISE$591
- GOCOVRI$505
- TYSABRI$300
- RELISTOR$162
- UPLIZNA$131
How this compares
$279,220 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $548,042 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $479,450 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 41 | $294,398 |
| IngrezzaValbenazine Tosylate | 26 | $217,070 |
| RexultiBrexpiprazole | 85 | $153,576 |
| RytaryCarbidopa/Levodopa | 203 | $121,547 |
| ZeposiaOzanimod Hydrochloride | 12 | $106,487 |
| Kesimpta PenOfatumumab | 12 | $105,342 |
| XcopriCenobamate | 73 | $105,261 |
| BotoxOnabotulinumtoxina | 47 | $64,248 |
| Memantine Hcl | 1,140 | $51,399 |
| Emgality PenGalcanezumab-Gnlm | 61 | $40,986 |
| GocovriAmantadine Hcl | 12 | $38,992 |
| Nurtec OdtRimegepant Sulfate | 19 | $33,696 |
| UbrelvyUbrogepant | 19 | $33,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $282 | $581,73941 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $456 | $479,45027 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,113 | $217,07026 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $29,101 | $153,57685 claims |
| Amneal Pharmaceuticals LLCRytary | $647 | $121,547203 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $49,325 | $114,03478 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $87 | $106,48712 claims |
| SK Life Science, Inc.Xcopri | $28,459 | $105,26173 claims |
| UCB, Inc.Briviact, Neupro | $3,117 | $50,74637 claims |
| MDD US Operations, LLCGocovri | $1,929 | $38,99212 claims |
| CSL BehringPrivigen | $303 | $30,04718 claims |
| Eisai Inc.Fycompa | $31,987 | $27,65618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Fresno
- Eric FarbmanFresno$866K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.